NVAX Novavax Inc.

5.62
+0.21  (+4%)
Previous Close 5.41
Open 5.41
Price To Book -0.88
Market Cap 131,916,540
Shares 23,472,694
Volume 526,819
Short Ratio
Av. Daily Volume 824,353

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 immunogenicity and safety data data released January 3, 2019. Phase 3 trial to be initiated in 2019.
NanoFlu vaccine
Influenza
Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu